Edwards Lifesciences’ stock experienced a significant surge following a stellar second-quarter 2025 earnings report. The medical device innovator exceeded revenue and earnings expectations, showcasing remarkable growth in its heart valve therapies. This exceptional performance led to an upward revision in the company’s full-year sales guidance, indicating a resurgence in its key markets. With sales growth of 11.9% (10.6% adjusted) and robust performance across all product groups, Edwards Lifesciences has demonstrated its ability to deliver outstanding results.
The company’s Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.1 billion, reflecting a substantial increase of 8.9% (7.8% on a constant currency basis). Moreover, the Transcatheter Mitral and Tricuspid Therapies (TMTT) segments achieved impressive sales growth of 61.9% year-over-year. In the Surgical segment, global sales surged by 7.7% compared to the previous year. CEO Bernard Zovighian expressed satisfaction with the strong second-quarter performance, emphasizing the company’s confidence in its full-year outlook and raising sales and EPS guidance.
Read more from finance.yahoo.com